What's in Todd C. Lee MD MPH FIDSA's pipeline?

Todd C. Lee MD MPH FIDSA has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Todd C. Lee MD MPH FIDSA's portfolio?

Top competitors by shared drug class: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/todd-c-lee-md-mph-fidsa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Todd C. Lee MD MPH FIDSA — Portfolio Competitive Intelligence Brief

Todd C. Lee MD MPH FIDSA pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Daptomycin for Injection	Daptomycin for Injection	marketed	Cyclic lipopeptide antibiotic	Bacterial cell membrane	Infectious Disease

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Todd C. Lee MD MPH FIDSA:

Cite this brief

Drug Landscape (2026). Todd C. Lee MD MPH FIDSA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/todd-c-lee-md-mph-fidsa. Accessed 2026-05-16.